Physician profile
John A Johnson
NPI 1720154131
$135,150.90
in general payments reported to CMS, 2019-2025
22 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $26K · 2021: $12K · 2022: $4,793 · 2023: $25K · 2024: $16K · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Food and Beverage: $3,590 · Travel and Lodging: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,406.25 |
| Food and Beverage | $3,589.79 |
| Travel and Lodging | $2,112.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $77,899.63 | 2019-2024 | Aristada, Vivitrol, Lybalvi |
| Axsome Therapeutics, INC. | $43,374.13 | 2022-2024 | Auvelity |
| Allergan, INC. | $5,348.14 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $5,064.32 | 2019-2022 | |
| Abbvie INC. | $836.10 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $504.06 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $333.70 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $330.27 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $306.76 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $205.93 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $141.27 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $128.21 | 2019 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Lilly USA, LLC | $121.85 | 2025 | Zepbound |
| Harmony Biosciences LLC | $112.56 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $95.09 | 2019 | |
| Corcept Therapeutics | $86.49 | 2024 | Korlym |
| Vanda Pharmaceuticals INC. | $78.96 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.03 | 2024 | Caplyta |
| Braeburn INC. | $14.49 | 2024 | Brixadi |
| Medline Industries Lp | $14.35 | 2022 | |
| Tris Pharma INC | $13.56 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.